Coeptis Therapeutics Holdings, Inc. reported a significant increase in revenue for the fiscal year ending December 31, 2025, generating $1.36 million compared to no revenue in the previous year. This revenue primarily stemmed from lead generation and webinar services offered through its NexGenAI platform. Despite this growth, the company continues to face challenges in achieving profitability, incurring a net loss of $12.28 million for 2025, an increase from a loss of $10.88 million in 2024. The accumulated deficit as of December 31, 2025, reached $109.95 million, raising concerns about the company's ability to sustain operations without additional capital.
The company's operating expenses rose to $14.23 million in 2025, up from $10.05 million in 2024. This increase was largely attributed to higher professional services expenses, including legal and consulting fees related to the company's merger activities, as well as increased stock-based compensation. Research and development expenses decreased to $1.28 million from $2.33 million, reflecting a strategic shift in focus following the termination of a shared services agreement with Deverra Therapeutics.
In terms of strategic developments, Coeptis entered into a significant licensing agreement with Deverra Therapeutics in August 2023, acquiring rights to a proprietary stem cell expansion platform. This agreement included a cash payment of approximately $570,000 and the issuance of 200,000 shares of common stock. Additionally, the company has been actively pursuing partnerships to enhance its product pipeline, particularly in the oncology and autoimmune markets. The company also announced a pending merger with Z Squared, expected to close in the second quarter of 2026, which will involve a spin-out of its biotechnology operations.
Operationally, Coeptis has maintained a lean workforce, with only six employees as of the end of 2025. The company has not reported significant customer growth metrics, but it has indicated plans to expand its market presence through strategic partnerships and product development initiatives. The company’s stock is listed on the Nasdaq Capital Market, and it has faced compliance challenges regarding its stock price, having previously received notices from Nasdaq regarding its bid price requirements.
Looking ahead, Coeptis anticipates continued losses as it invests in product development and seeks to establish itself in the competitive biopharmaceutical landscape. The company is focused on raising additional capital to support its operations and growth strategy, with management expressing optimism about future revenue generation from its product candidates and technology platforms. However, the uncertainty surrounding its ability to achieve profitability and the need for ongoing financing remain critical factors for stakeholders to consider.
About Coeptis Therapeutics Holdings, Inc.
Coeptis Therapeutics Holdings, Inc. is a biopharmaceutical company focused on developing innovative cell and antibody therapies for cancer and viral infections. Its core activities include advancing natural killer (NK) cell platforms, CAR T-cell technologies, and diagnostic tools. The company collaborates with academic and industry partners to develop targeted treatments, aiming to improve efficacy and safety in oncology and infectious disease markets.
About 10-K Filings
A 10-K form is a comprehensive annual report that public companies in the United States must file with the SEC, providing a detailed overview of the company's financial condition, performance, and business strategies.
Key points about the 10-K:
- Frequency: Filed annually, typically within 60 to 90 days after the end of the company's fiscal year.
-
Content: It includes:
- Detailed financial statements audited by an independent accounting firm
- Management's Discussion and Analysis (MD&A) of financial condition and results
- Description of the company's business, properties, and legal proceedings
- Risk factors and market risks
- Executive compensation and corporate governance information
- Importance: Considered the most comprehensive and important document a public company files with the SEC.
- Length: Often exceeds 100 pages due to its extensive and detailed nature.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.